Egis World
Tue, Jul 5, 2022 11:04 AM

Csaba Poroszlai is CEO of Egis Pharmaceuticals PLC

Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.
Egis World

Csaba Poroszlai is CEO of Egis Pharmaceuticals PLC

Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.
Tue, Jul 5, 2022 11:04 AM
Author:
Tue, Jul 5, 2022 11:04 AM
Author:

Csaba Poroszlai started his professional career at Béres Pharmaceuticals Co. in 1998. Holding the position of Chief Financial Officer between 2003 and 2008, he gained outstanding professional and sectoral experience. Csaba Poroszlai joined Egis in 2008: as Head of Strategic Controlling, he was responsible for the development of high priority controlling systems. In 2011, he was appointed Chief Financial Officer and became a member of the Board of Directors of Egis.

 The appointment of Csaba Poroszlai ends the interim period which started in February this year when, following the former CEO’s departure, he was asked to temporarily fill the position until the selection process for a new CEO is completed.

During his term as interim CEO, Csaba Poroszlai was supported by Balázs Vándor Chief Accountant and Deputy Chief Financial Officer. At the same time as this decision, Balázs Vándor was appointed Chief Financial Officer.

 Balázs Vándor joined Egis in 1995. From 2003 he worked as deputy chief accountant, then, after a short assignment as chief internal audit officer from 2010 he held the positions of chief accountant, deputy accounting director and then accounting director.

 Egis is one of the region’s significant generic pharmaceutical companies. Its products are available in sixty-one countries, appr. thirty million patients are treated with Egis medicines yearly. As one of Hungary’s leading generic manufacturers, Egis sells the most prescription medicines in pharmacies in Hungary. To treat cardiovascular disease, doctors most often choose Egis medications for their patients, while Egis products are the second most common therapeutic indication for central nervous system diseases in our country. *

*Source: MAT04 2022 IQVIA (May 2021 – April 2022)

#management
Related articles from Egis Magazine
Our People

Dr Csaba Pácz confirmed as Commercial Director of Egis Group
More
Our People

Change in the management of the Commercial Directorate
More
Egis World

Csaba Poroszlai elected vice president of MAGYOSZ
More

Cookie Settings

Egis’s website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.

Cookies necessary for basic functioning

These cookies ensure the appropriate functioning of the website, facilitate its use and collect information on its use without identifying visitors.

Functional cookies

In order to enhance the user experience, we use cookies which record the use of certain functions of the website, thus enabling users to have the same settings at the time of their next visit.

Cookies for statistical purposes

They provide statistical data on the performance of the website (such as number of page loads, average time spent on the website) in order to collect data for the operator of the website on the website usage patterns of users. These cookies do not identify visitors, information collected by them relate to the number of subpages visited by the user, the length of each session, the types of error messages, etc. Cookies for statistical purposes are automatically placed on the user’s devices during browsing, and you can delete such cookies in the browser settings.
Details
I Agree
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox